Mackenzie Financial Adds $1M in Abbott Laboratories ($ABT)
Mackenzie Financial increased its position in Abbott Laboratories by 1.1% in its latest filing.
Key Points
- Mackenzie Financial increased its stake in Abbott Laboratories by 1.1%, adding 16,002 shares to hold a total of 1,473,375 shares.
- Abbott Laboratories trades at $93.35 with a market cap of $162.4 billion and a P/E ratio of 26.12.
- Analysts maintain a 'buy' consensus with a target mean price of $116.54, supported by recent insider buying activity.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mackenzie Financial has increased its stake in Abbott Laboratories (NYSE:ABT) by 1.1%, according to its latest 13F filing with the SEC. The firm added 16,002 shares during the reporting period, bringing its total holdings to 1,473,375 shares valued at approximately $137.5 million.
Mackenzie Financial vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Mackenzie Financial's Abbott Laboratories Position
Mackenzie Financial boosted its position in Abbott Laboratories by 1.1%, adding 16,002 shares to its portfolio. This move increased its total holdings to 1,473,375 shares. The value of this position is now approximately $137.5 million, reflecting the firm's continued interest in the healthcare giant.
Other Institutional Activity in Abbott Laboratories
Several other major funds also adjusted their holdings in Abbott Laboratories. BlackRock, Inc. reduced its stake by 1,221,310 shares, ending with 145,687,458 shares valued at about $14.96 billion, a 0.8% decrease. Vanguard Capital Management LLC opened a new position with 112,949,933 shares worth approximately $11.60 billion. State Street Corp trimmed its holdings by 278,314 shares, now holding 79,575,468 shares valued at around $8.17 billion, a 0.3% decrease. Capital Research Global Investors increased its position by 10,606,123 shares, a 27.1% increase, to hold 49,775,362 shares valued at $5.11 billion. Charles Schwab Investment Management Inc significantly boosted its holdings by 32,310,527 shares, a 245% increase, reaching 45,500,055 shares worth about $4.67 billion.
Abbott Laboratories Stock Down 17.3%
Shares of Abbott Laboratories traded near $93.35 on Friday. The company, with a market cap of $162.4 billion, has a P/E ratio of 26.12 and a forward P/E of 15.39. Abbott's beta is 0.62, indicating lower volatility than the market. The stock's 52-week range is between $81.97 and $137.49, with a 50-day moving average of $89.27 and a 200-day moving average of $112.80. The company maintains a strong financial position with a current ratio of 1.39 and a debt-to-equity ratio of 64.77.
$ABT stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Abbott Laboratories reported revenue of $45.13 billion, reflecting a growth of 7.8%. The company achieved a net margin of 13.9% and a return on equity of 12.3%. Earnings per share came in at $3.57. Abbott is expected to release its next earnings report on July 16, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Abbott Laboratories offers an annual dividend rate of $2.52, yielding 2.7%. The payout ratio stands at 67.23%, providing a steady income stream to its shareholders.
Insider Buying and Selling at Abbott Laboratories
Recent insider activity at Abbott Laboratories includes several purchases. On May 7, 2026, John Stratton acquired 2,000 shares at $86.82 each. Mary Moreland, the Executive Vice President, bought 5,314 shares at $94.41 on April 28, 2026. On April 27, 2026, Daniel Starks purchased 10,000 shares at $92.65. Additional buys on April 24, 2026, included Nita Ahuja and Sally Blount, each acquiring 2,286 shares.
Analysts Set New Price Targets
Analysts remain optimistic about Abbott Laboratories. On June 22, 2026, Piper Sandler reiterated its 'buy' rating with a price target of $115. Barclays maintained a 'buy' rating with a target of $143 on April 20, 2026. Overall, the consensus among 24 analysts is a 'buy', with a target mean price of $116.54.
About Abbott Laboratories
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois. It operates in the medical devices industry and employs around 122,000 people. Led by CEO Mr. Philip P. Boudreau, Abbott develops and sells a wide range of healthcare products, including pharmaceuticals, diagnostics, nutritionals, and medical devices. The company was founded in 1888 and has a long history of innovation in healthcare.
Bottom Line
Mackenzie Financial's decision to increase its stake in Abbott Laboratories signals confidence in the company's future prospects. As a key player in the healthcare sector, Abbott's strong financials and consistent dividend make it a stock to watch. Keep in mind that 13F filings are backward-looking and may not reflect current positions.
Get Abbott Laboratories alerts
New 13F filings, insider trades, and analyst moves on $ABT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.